Pharma companies set for strong performance in March 2025 quarter amid earning (...)
Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic therapies in India.
Site référencé: The Economic Times
The Economic Times
Can markets defy historical trends and thrive in May amid global challenges ?
2/05/2025
SBFC Finance risk officer, chief of operations step down
1er/05/2025
Rs 2,600-crore deal : Carlyle looks to exit PNB Housing
1er/05/2025
Ryanair threatens to seek alternative to Boeing order if tariffs impact price
1er/05/2025
Tata Tech, Reliance, Gensol, and sector watch : Kranthi Bathini's 2025 market outlook
1er/05/2025
Should F&O trading require a licence ? Vijay Kedia slams retail frenzy for turning markets into a casino
1er/05/2025
